ROBIN PARK: Open Payments
NPI 1407871213 · CREVE COEUR, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,076 in 62 payments from 11 companies in 2025. Trend: 2023 $966 · 2024 $1,046 · 2025 $1,076
Food & beverage: $1,000Education: $76
| Company | Payments | Amount |
|---|---|---|
| Corium, LLC | 35 | $491 |
| Teva Pharmaceuticals USA, Inc. | 4 | $142 |
| Neurocrine BioSciences, Inc. | 7 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Supernus Pharmaceuticals, Inc. | 3 | $65 |
| Neos Therapeutics, LP | 3 | $52 |
| Janssen Pharmaceuticals, Inc | 2 | $39 |
| ABBVIE INC. | 1 | $24 |
| Tris Pharma Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: Azstarys, INGREZZA, TRINTELLIX, AUSTEDO XR, Qelbree, SPRAVATO, Adzenys XR-ODT, VRAYLAR.
Industry payments across MO — which companies pay providers there.
